Victory Capital Management Inc. Sells 2,505 Shares of Ascendis Pharma A/S (NASDAQ:ASND) (2025)

Victory Capital Management Inc. cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,353 shares of the biotechnology company's stock after selling 2,505 shares during the period. Victory Capital Management Inc. owned 0.22% of Ascendis Pharma A/S worth $18,083,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $1,725,000. New York State Common Retirement Fund raised its position in shares of Ascendis Pharma A/S by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock valued at $28,151,000 after buying an additional 25,164 shares in the last quarter. Rice Hall James & Associates LLC raised its position in shares of Ascendis Pharma A/S by 2.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after buying an additional 3,274 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $203,000.

Analyst Ratings Changes

ASND has been the topic of several analyst reports. Evercore ISI boosted their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Wedbush restated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Stifel Nicolaus boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a report on Friday, November 15th. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, February 25th. Finally, Oppenheimer dropped their target price on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating on the stock in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $202.36.

View Our Latest Stock Report on Ascendis Pharma A/S

Ascendis Pharma A/S Stock Up 0.4 %

ASND stock traded up $0.67 during trading on Friday, reaching $152.98. The stock had a trading volume of 405,736 shares, compared to its average volume of 456,030. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $158.00. The company's 50 day moving average is $138.06 and its two-hundred day moving average is $134.64. The company has a market capitalization of $9.28 billion, a price-to-earnings ratio of -21.55 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

(Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Recommended Stories

• Five stocks we like better than Ascendis Pharma A/S
• The How and Why of Investing in Gold Stocks
• Ignore Reports, Apple Won't Install Starlink with iOS 18.3
• 3 Best Fintech Stocks for a Portfolio Boost
• Casey’s Uptrend Remains Strong—New Highs on the Horizon
• What is an Earnings Surprise?
• Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead

Should You Invest $1,000 in Ascendis Pharma A/S Right Now?

Before you consider Ascendis Pharma A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.

While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here